Tier 4 — mechanistic

Commentary: Efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial

Junpeng Qiu, Fangjun Xiao, Junxing Yang
Frontiers in Nutrition 2025 12:1712455

Bibliography

Funding
Commentary authors report no financial support.
Competing interests
Commentary authors declared no commercial or financial conflicts.

Study snapshot

DesignIndependent published methodological commentary on Park et al. 2025 OA RCT.
ModelCritique of a trial of 80 adults with knee OA.
SampleNo new participants; commentary on published RCT.
InterventionNo new intervention.
DurationNot applicable.
EndpointsRandomization balance; Attrition; Per-protocol versus ITT; Clinical significance; VAS versus WOMAC consistency

What the study showed, in plain terms

An independent commentary highlighted major limitations in the 2025 low-molecular-weight collagen OA trial, including baseline disease-severity imbalance, about 25% dropout, reliance on per-protocol analysis and inconsistent WOMAC versus VAS pain outcomes. It cautioned against treating a modest symptom signal as proven cartilage repair.

Key findings

The authors observed baseline KL grade imbalance, about 25% attrition, WOMAC pain but not VAS significance (p=0.299 for VAS), and no meaningful imaging/inflammatory-marker signal of disease modification.

What this study can and cannot tell us

This article is interpretive commentary, not an additional randomized trial or independent replication. Methodological critiques should be attributed to the commentary authors; they do not independently prove the original study's finding false.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified